BiotechTube
Bespak

Bespak

King's Lynn, United Kingdom· Est.
bespak.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Bespak is a leading specialist CDMO in the inhalation and nasal drug delivery space, with a legacy dating back to 1969. The company is at the forefront of the industry's sustainability transition, actively developing and scaling manufacturing for low Global Warming Potential (GWP) propellants for pMDIs. Its core business involves providing end-to-end services and proprietary device platforms, such as the widely adopted BK357 valve, to pharmaceutical partners globally, helping them bring combination products to market.

Respiratory

Technology Platform

Specialist CDMO offering end-to-end development and manufacturing for inhaled and nasal drug-device combination products. Core platforms include pMDI valves (BK357), actuators, Dry Powder Inhalers (DPIs), Soft Mist Inhalers, and nasal delivery systems, with a leading focus on compatibility with low-GWP propellants (HFO-1234ze, HFA-152a).

Funding History

2
Total raised:$35M
Series B$25M
Series A$10M

Opportunities

The global regulatory and environmental push to replace high-GWP propellants in inhalers creates a massive, multi-year transition opportunity for Bespak as a first-mover in low-carbon pMDI manufacturing.
Additionally, the growing pipeline of biologic and complex generic drugs requiring sophisticated delivery devices expands the addressable market for its specialist CDMO services.

Risk Factors

The commercial success of low-GWP propellants is not fully assured, dependent on final regulatory approvals, supply chain stability, and broad market adoption, which could delay the return on Bespak's significant investment.
As a CDMO, the company also faces customer concentration risk and competitive pressure from other device manufacturers and pharmaceutical companies developing in-house capabilities.

Competitive Landscape

Bespak competes with other established drug delivery and device manufacturing companies such as Aptar Pharma, Nemera, and Kindeva Drug Delivery (formerly 3M's drug delivery business). Its key competitive advantages are its deep, specialized heritage in inhalation, its market-leading BK357 valve platform, and its early-mover investment in scalable manufacturing for sustainable propellants.

More companies in Drug Delivery & Formulation →More companies in United Kingdom →